The molecular rationale of Src inhibition in colorectal carcinomas

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2019-2029

  Gargalionis, Antonios N ^a   Karamouzis, Michalis V ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

clinical trial; Colorectal cancer; EGFR; Src; tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; BOSUTINIB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IXABEPILONE; KETOCONAZOLE; KX2 391; OXALIPLATIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; SARACATINIB; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN ANTIBODY; XL 228; XL 999;

CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; HUMAN; METASTASIS; MITOGENESIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECOMMENDED DRUG DOSE; REVIEW; STRUCTURE ANALYSIS; TREATMENT RESPONSE; TUMOR INVASION; TUMOR VASCULARIZATION;

CLINICAL TRIAL; COLORECTAL CANCER; EGFR; SRC; TYROSINE KINASE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 84896691166     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28299     Document Type: Review

References (106)

1. Yeatman TJ, A renaissance for SRC. Nat Rev Cancer 2004; 4: 470-80.
2. Wheeler DL, Iida M, Dunn EF,. The role of Src in solid tumors. Oncologist 2009; 14: 667-78.
3. Han NM, Curley SA, Gallick GE,. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res 1996; 2: 1397-404.
4. Rosenbluh J, Nijhawan D, Cox AG, et al,. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151: 1457-73.
5. Sancier F, Dumont A, Sirvent A, et al,. Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. PLoS One 2011; 6: e17237.
6. Sirvent A, Benistant C, Roche S,. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res 2012; 2: 357-71.
7. Boggon TJ, Eck MJ,. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918-27.
8. Perez Y, Maffei M, Igea A, et al,. Lipid binding by the Unique and SH3 domains of c-Src suggests a new regulatory mechanism. Sci Rep 2013; 3: 1295.
9. Engen JR, Wales TE, Hochrein JM, et al,. Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci 2008; 65: 3058-73.
10. Bolen JB, Veillette A, Schwartz AM, et al,. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 1987; 84: 2251-5.
11. Talamonti MS, Roh MS, Curley SA, Gallick GE,. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993; 91: 53-60.
12. Cartwright CA, Meisler AI, Eckhart W,. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 1990; 87: 558-62.
13. Termuhlen PM, Curley SA, Talamonti MS, et al,. Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res 1993; 54: 293-8.
14. Aligayer H, Boyd DD, Heiss MM, et al,. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94: 344-51.
15. Leroy C, Fialin C, Sirvent A, et al,. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res 2009; 69: 2279-86.
16. Sirvent A, Vigy O, Orsetti B, et al,. Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts. Mol Cell Proteomics 2012; 11: 1937-50.
17. Oneyama C, Hikita T, Enya K, et al,. The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 2008; 30: 426-36.
18. Sirvent A, Benistant C, Pannequin J, et al,. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 2010; 29: 1303-15.
19. Irby R, Mao W, Coppola D, et al,. Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential. Cell Growth Differ 1997; 8: 1287-95.
20. Welman A, Cawthorne C, Ponce-Perez L, et al,. Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. Neoplasia 2006; 8: 905-16.
21. Malek RL, Irby RB, Guo QM, et al,. Identification of Src transformation fingerprint in human colon cancer. Oncogene 2002; 21: 7256-65.
22. Okada M,. Regulation of the SRC family kinases by Csk. Int J Biol Sci 2012; 8: 1385-97.
23. Cam WR, Masaki T, Shiratori Y, et al,. Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma. Cancer 2001; 92: 61-70.
24. Nakagawa T, Tanaka S, Suzuki H, et al,. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int J Cancer 2000; 88: 384-91.
25. Kunte DP, Wali RK, Koetsier JL, et al,. Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett 2005; 579: 3497-502.
26. Roskoski R, Jr., Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005; 331: 1-14.
27. Zheng X, Resnick RJ, Shalloway D,. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi. Int J Cancer 2008; 122: 1999-2007.
28. Huang J, Yao L, Xu R, et al,. Activation of Src and transformation by an RPTPalpha splice mutant found in human tumours. EMBO J 2011; 30: 3200-11.
29. Krndija D, Schmid H, Eismann JL, et al,. Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility. Oncogene 2010; 29: 2724-38.
30. Zhu S, Bjorge JD, Fujita DJ,. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 2007; 67: 10129-37.
31. Irby RB, Mao W, Coppola D, et al,. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21: 187-90.
32. Daigo Y, Furukawa Y, Kawasoe T, et al,. Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients. Cancer Res 1999; 59: 4222-4.
33. Laghi L, Bianchi P, Orbetegli O, et al,. Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. Br J Cancer 2001; 84: 196-8.
34. Nilbert M, Fernebro E,. Lack of activating c-SRC mutations at codon 531 in rectal cancer. Cancer Genet Cytogenet 2000; 121: 94-5.
35. Wang NM, Yeh KT, Tsai CH, et al,. No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese. Cancer Lett 2000; 150: 201-4.
36. Greenman C, Stephens P, Smith R, et al,. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
37. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
38. Gargalionis AN, Piperi C, Papavassiliou AG,. Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int J Biochem Cell Biol 2012; 44: 1276-89.
39. Hirsch CL, Smith-Windsor EL, Bonham K,. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. Int J Cancer 2006; 118: 547-54.
40. Lee JC, Maa MC, Yu HS, et al,. Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells. Mol Carcinog 2005; 43: 207-14.
41. Suzuki K, Oneyama C, Kimura H, et al,. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway. J Biol Chem 2011; 286: 15698-706.
42. Oneyama C, Morii E, Okuzaki D, et al,. MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene 2012; 31: 1623-35.
43. Roche S, Fumagalli S, Courtneidge SA,. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science 1995; 269: 1567-9.
44. Kilkenny DM, Rocheleau JV, Price J, et al,. c-Src regulation of fibroblast growth factor-induced proliferation in murine embryonic fibroblasts. J Biol Chem 2003; 278: 17448-54.
45. Wilson LK, Luttrell DK, Parsons JT, et al,. pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol 1989; 9: 1536-44.
46. Zhang X, Meng J, Wang ZY,. A switch role of Src in the biphasic EGF signaling of ER-negative breast cancer cells. PLoS One 2012; 7: e41613.
47. Jones RJ, Avizienyte E, Wyke AW, et al,. Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 2002; 87: 1128-35.
48. Mamidipudi V, Cartwright CA,. A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. Oncogene 2009; 28: 4421-33.
49. Mamidipudi V, Dhillon NK, Parman T, et al,. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene 2007; 26: 2914-24.
50. Lopez J, Hesling C, Prudent J, et al,. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik. Cell Death Differ 2012; 19: 1459-69.
51. Kanda S, Miyata Y, Kanetake H, et al,. Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med 2007; 20: 113-21.
52. Jia J, Starodub A, Cushman I, et al,. Dual inhibition of alphaV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer Drugs 2012; 24: 237-50.
53. Laird AD, Li G, Moss KG, et al,. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2003; 2: 461-9.
54. Ellis LM, Staley CA, Liu W, et al,. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 1998; 273: 1052-7.
55. Fleming RY, Ellis LM, Parikh NU, et al,. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery 1997; 122: 501-7.
56. Lesslie DP, Summy JM, Parikh NU, et al,. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006; 94: 1710-7.
57. Zhao X, Guan JL,. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 2011; 63: 610-5.
58. Boyer B, Roche S, Denoyelle M, et al,. Src and Ras are involved in separate pathways in epithelial cell scattering. EMBO J 1997; 16: 5904-13.
59. Avizienyte E, Brunton VG, Fincham VJ, et al,. The SRC-induced mesenchymal state in late-stage colon cancer cells. Cells Tissues Organs 2005; 179: 73-80.
60. Avizienyte E, Keppler M, Sandilands E, et al,. An active Src kinase-beta-actin association is linked to actin dynamics at the periphery of colon cancer cells. Exp Cell Res 2007; 313: 3175-88.
61. Vitale S, Avizienyte E, Brunton VG, et al,. Focal adhesion kinase is not required for Src-induced formation of invadopodia in KM12C colon cancer cells and can interfere with their assembly. Eur J Cell Biol 2008; 87: 569-79.
62. Gianni D, Taulet N, DerMardirossian C, et al,. c-Src-mediated phosphorylation of NoxA1 and Tks4 induces the reactive oxygen species (ROS)-dependent formation of functional invadopodia in human colon cancer cells. Mol Biol Cell 2010; 21: 4287-98.
63. Irby RB, Yeatman TJ,. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002; 62: 2669-74.
64. Windham TC, Parikh NU, Siwak DR, et al,. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-807.
65. Bromann PA, Korkaya H, Courtneidge SA,. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004; 23: 7957-68.
66. Sekharam M, Nasir A, Kaiser HE, Coppola D,. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 2003; 23: 1517-24.
67. Emaduddin M, Bicknell DC, Bodmer WF, et al,. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A 2008; 105: 2358-62.
68. Mao W, Irby R, Coppola D, et al,. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997; 15: 3083-90.
69. Organ SL, Tong J, Taylor P, et al,. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. J Proteome Res 2011; 10: 3200-11.
70. Kopetz S,. Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res 2007; 1: S37-41.
71. Biscardi JS, Maa MC, Tice DA, et al,. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999; 274: 8335-43.
72. Kloth MT, Laughlin KK, Biscardi JS, et al,. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 2003; 278: 1671-9.
73. Maa MC, Leu TH, McCarley DJ, et al,. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 1995; 92: 6981-5.
74. Poole EM, Curtin K, Hsu L, et al,. Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. Int J Mol Epidemiol Genet 2011; 2: 300-15.
75. Brunton VG, Ozanne BW, Paraskeva C, et al,. A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 1997; 14: 283-93.
76. Buchanan FG, Gorden DL, Matta P, et al,. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 2006; 103: 1492-7.
77. Montero JC, Seoane S, Ocana A, et al,. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17: 5546-52.
78. Serrels A, Macpherson IR, Evans TR, et al,. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014-22.
79. Green TP, Fennell M, Whittaker R, et al,. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009; 3: 248-61.
80. Arcaroli JJ, Touban BM, Tan AC, et al,. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res 2010; 16: 4165-77.
81. Golas JM, Lucas J, Etienne C, et al,. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005; 65: 5358-64.
82. Demetri GD, Lo Russo P, MacPherson IR, et al,. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 6232-40.
83. Sharma MR, Wroblewski K, Polite BN, et al,. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 2012; 30: 1211-5.
84. Baselga J, Cervantes A, Martinelli E, et al,. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010; 16: 4876-83.
85. Daud AI, Krishnamurthi SS, Saleh MN, et al,. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 2012; 18: 1092-100.
86. Argiris A, Feinstein TM, Wang L, et al,. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs 2012; 30: 1575-84.
87. Herbolsheimer P, Kapoor R, Smith KL, et al,. Phase I trial of dasatinib and ixabepilone in patients with solid tumors. Invest New Drugs 2012; 31: 92-8.
88. Hong DS, Choe JH, Naing A, et al,. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 2012; [Epub ahead of print].
89. Isakoff S, Wang D, Campone M, et al,. A phase I dose-escalation study of bosutinib plus capecitabine in selected advanced solid tumors. Molecular Cancer Therapeutics 2011;10: DOI: 10.1158/1535-7163.TARG-11-A91.
90. Johnson FM, Agrawal S, Burris H, et al,. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010; 116: 1582-91.
91. Kaye S, Aamdal S, Jones R, et al,. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer 2012; 106: 1728-34.
92. Lieu CH, Wolff RA, Eng C, et al,. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. J Clin Oncol 2010; 28: 3536.
93. Starodub A, Cohn AL, Arrowood C, et al,. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. J Clin Oncol 2011; 29: 513.
94. Trarbach T, Schultheis B, Gauler TC, et al,. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Invest New Drugs 2012; 30: 1962-71.
95. Kopetz S, Lesslie DP, Dallas NA, et al,. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009; 69: 3842-9.
96. Morrow CJ, Ghattas M, Smith C, et al,. Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Cancer Res 2010; 70: 5931-41.
97. Mologni L, Cleris L, Magistroni V, et al,. Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 2009; 124: 1990-6.
98. Wheeler DL, Iida M, Kruser TJ, et al,. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009; 8: 696-703.
99. Dunn EF, Iida M, Myers RA, et al,. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 2011; 30: 561-74.
100. Brand TM, Wheeler DL,. KRAS mutant colorectal tumors: past and present. Small GTPases 2012; 3: 34-9.
101. Zhang S, Yu D,. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012; 33: 122-8.
102. Takahashi S, Miyazaki M, Okamoto I, et al,. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Cancer Sci 2011; 102: 2058-64.
103. Fujisaka Y, Onozawa Y, Kurata T, et al,. First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Invest New Drugs 2012; 31: 108-14.
104. Cripe L, McGuire W, Wertheim M, et al,. XL999 phase 2 study group, Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). J Clin Oncol 2007; 25: 3591.
105. Adjei AA, Cohen RB, Kurzrock R, et al,. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol 2009; 27: 3511.
106. Smith DC, Britten C, Garon EB, et al,. A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. J Clin Oncol 2010; 28: 3105.